Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Open accessThe DOI matches its Crossref record; 66 of the 68 references it cites were found in a registry or an index.
Abstract
Background: Cancer-associated fibroblasts (CAFs) are tumor-promoting and correlate with poor survival in many cancers, which has led to their emergence as potential therapeutic targets. However, effective methods to manipulate these cells clinically have yet to be developed. Methods: CAF accumulation and prognostic significance in head and neck cancer (oral, n = 260; oropharyngeal, n = 271), and colorectal cancer (n = 56) was analyzed using immunohistochemistry. Mechanisms regulating fibroblast-to-myofibroblast transdifferentiation were investigated in vitro using RNA interference/pharmacological inhibitors followed by polymerase chain reaction (PCR), immunoblotting, immunofluorescence, and functional assays. RNA sequencing/bioinformatics and immunohistochemistry were used to analyze NAD(P)H Oxidase-4 (NOX4) expression in different human tumors. NOX4's role in CAF-mediated tumor progression was assessed in vitro, using CAFs from multiple tissues in Transwell and organotypic culture assays, and in vivo, using xenograft (n = 9-15 per group) and isograft (n = 6 per group) tumor models. All statistical tests were two-sided. Results: Patients with moderate/high levels of myofibroblastic-CAF had a statistically significant decrease in cancer-specific survival rates in each cancer type analyzed (hazard ratios [HRs] = 1.69-7.25, 95% confidence intervals [CIs] = 1.11 to 31.30, log-rank P ≤ .01). Fibroblast-to-myofibroblast transdifferentiation was dependent on a delayed phase of intracellular reactive oxygen species, generated by NOX4, across different anatomical sites and differentiation stimuli. A statistically significant upregulation of NOX4 expression was found in multiple human cancers (P < .001), strongly correlating with myofibroblastic-CAFs (r = 0.65-0.91, adjusted P < .001). Genetic/pharmacological inhibition of NOX4 was found to revert the myofibroblastic-CAF phenotype ex vivo (54.3% decrease in α-smooth muscle actin [α-SMA], 95% CI = 10.6% to 80.9%, P = .009), prevent myofibroblastic-CAF accumulation in vivo (53.2%-79.0% decrease in α-SMA across different models, P ≤ .02) and slow tumor growth (30.6%-64.0% decrease across different models, P ≤ .04). Conclusions: These data suggest that pharmacological inhibition of NOX4 may have broad applicability for stromal targeting across cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Effect of NOX4 stromal targeting in vitro and in vivo. A) Immunoblotting analysis of NOX4 expression in patient matched cancer-associated fibroblasts (CAFs) and normal fibroblasts cultured ex vivo from esophageal tissue biopsies (n = 6; statistical significance was assessed by a two-tailed ratio paired t test) (representative blot shown in Supplementary Figure 4A, available online). B) Immunofluorescent cytochemistry and immunoblotting for α-smooth muscle actin (α-SMA) expression (the percentage of cells positive for α−SMA stress fibers in each condition is shown; scale bar represents 50 µm) in CAFs isolated from head and neck squamous cell carcinoma (HNSCC) transduced with shRNA targeting NOX4 (MOI = 20) (knockdown confirmed in Supplementary Figure 4B, available online). C–E) CAFs (n = 7; isolated from HNSCC, n = 1), esophageal adenocarcinoma (EAC; n = 2), colorectal carcinoma (CRC; n = 3) and non–small cell lung carcinoma (NSCLC; n = 1) were treated with GKT137831 (20 µM, 5 days) and analyzed by immunoblotting (C) (mean +/− 95% confidence intervals [CIs], n = 7); intracellular ROS assay (D) (mean +/− 95% CIs, n = 3 [1-HNSCC and 2-EAC]; and CRC or NSCLC cell lines’ (SW480 and H441) Transwell migration toward conditioned media generated by anatomically matched normal fibroblasts or CAFs (mean +/− 95% CIs, n = 4 [3-CRC and 1-NSCLC]). C–E) Statistical significance was assessed by two-tailed t test with Welch’s correction. F–I) 5PT + human foetal foreskin fibroblasts (HFFF2s) (transduced as per Supplementary Figure 2B, available online) grown in organotypic culture (F) or RAG1−/− mice (G–I). F) Invasive index was quantified and statistical significance assessed by two-tailed t test with Welch’s correction. H) Tumor growth curves (mean + 95% CIs, n = 14–15/group; statistical significance was assessed by two-tailed homoscedastic t test). I) α-SMA immunohistochemistry (IHC) staining representative images and quantification (mean +/−95% CIs, n = 9-10/group; statistical significance was assessed by two-tailed homoscedastic t test). J–L) 5PT + HFFF2 xenograft tumors were grown in RAG1−/− mice for four days and then treated with GKT137831 (30 mg/kg) by daily oral gavage. K) Tumor growth curves (mean + 95% CIs, n = 8/group; statistical significance was assessed by two-tailed homoscedastic t test). L) α-SMA IHC staining, representative images, and quantification (mean +/− 95% CIs, n = 8/group; statistical significance was assessed by two-tailed t test with Welch’s correction). Scale bars represent 100 µm unless otherwise stated. Please see Supplementary Figures 4 and 5 (available online) for more information. CAF = cancer-associated fibroblasts; HFFF = human fetal foreskin fibroblasts; IHC = immunohistochemistry; NOF = normal fibroblasts; s.c. = subcutaneous; SMA = smooth muscle actin.](https://figures.cochat.ai/paper-figures/60e0a08a837644d39663441f33c3cb91/targeting-the-myofibroblastic-cancer-associated-fibroblast-phenotype-through-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NOX4 expression is closely related to CAF accumulation in myofibroblasts in patients with CRC, which may be attributed to the fact that NOX4 regulates the transdifferentiation from fibroblasts to myofibroblasts through the delayed period of intracellular ROS production, and the inhibition of NOX4 can effectively reduce the accumulation of CAF [53].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [53]
In the citing paper
“NOX4 expression is closely related to CAF accumulation in myofibroblasts in patients with CRC, which may be attributed to the fact that NOX4 regulates the transdifferentiation from fibroblasts to myofibroblasts through the delayed period of intracellular ROS production, and the inhibition of NOX4 can effectively reduce the accumulation of CAF [53].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 2×
“Over recent years, research has highlighted the contribution of the microenvironment to tumor progression (1), and numerous studies have documented the tumor-promoting role of cancerassociated fibroblasts (CAFs) (2–5).”
BackgroundWGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“(29) using single-cell RNA sequencing (FAP, THY1, DCN, COL1A1/2, and COL6A1/2/3; NOX4 correlation meta values 1⁄4 25.”
MethodOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 1×
“Given the previously described roles for CAFs in promoting resistance to chemotherapy (64,65) and adaptive antitumor immunity (4,66), stromal depletion through NOX4 inhibition may be a useful adjunct to improve response to current chemoand immunotherapeutics in patients with a-SMA-positive CAFrich tumors.”
BackgroundStromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Cited by
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Targeting ROS in cancer: rationale and strategies
Glorieux, C., Liu, S., Trachootham, D., & Huang, P. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00979-4 · Cited by 651
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 551
Fibroblasts in cancer: Unity in heterogeneity
Chhabra, Y., & Weeraratna, A. T. (2023) · Cell · doi:10.1016/j.cell.2023.03.016 · Cited by 474
Ford, K., Hanley, C. J., Mellone, M., Szyndralewiez, C., Heitz, F., Wiesel, P., Wood, O., Machado, M., Lopez, M.-A., Ganesan, A.-P., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3158 · Cited by 411
“A significant proportion of most solid cancers are CAF-rich (including metastasis); for example, over 50% of cases of head and neck, esophageal, colorectal, and pancreatic cancers are dominated by the presence of CAFs, and these are associated with poor prognosis (21).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., Smith, D. M., Harden, E., Szyndralewiez, C., Bullock, M., Noble, F., Moutasim, K. A., King, E. V., Vijayanand, P., Mirnezami, A. H., Underwood, T. J., Ottensmeier, C. H., & Thomas, G. J.
- Affiliations
- University of Southampton (GB)
- Genkyotex SA, Plan-les-Ouates, Switzerland
- La Jolla Institute for Immunology (US)
- Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK
- Corresponding author
- Thomas, Gareth J
- ORCID
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-03
- Volume
- 110
- Issue
- 1
- Pages
- 109-120
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC5903651
- OpenAlex
- W2739944480
- Cited by
- 195
- References
- 68
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 20 · 2023: 28 · 2022: 31 · 2021: 28 · 2020: 25 · 2019: 15 · 2018: 17 · 2017: 1
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Funders
- Cancer Research UK (C21825/A13315, C115121/A20256)
- National Cancer Institute (C21825/A13315, C115121/A20256)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- cancer-associated fibroblasts, myofibroblastic phenotype, NOX4, fibroblast-to-myofibroblast transdifferentiation, reactive oxygen species, head and neck cancer, oral cancer, oropharyngeal cancer, colorectal cancer, cancer-specific survival, tumor microenvironment, alpha-smooth muscle actin
- MeSH terms
- Cancer-Associated Fibroblasts, NADPH Oxidase 4, Actins, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Animals, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cell Count, Esophageal Neoplasms, Female, Head and Neck Neoplasms, Humans, Lung Neoplasms, Male, Middle Aged, Mouth Neoplasms, Neoplasm Transplantation, Oropharyngeal Neoplasms, Phenotype, Pyrazoles, Pyridines, Pyridones, Colorectal Neoplasms, Up-Regulation, Survival Rate, Reactive Oxygen Species, Disease Progression, NADPH Oxidases, RNA Interference, Pyrazolones, Mice, Cell Transdifferentiation, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. https://app.cochat.ai/papers/10.1093/jnci/djx121
- The paper
- Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., Smith, D. M., Harden, E., Szyndralewiez, C., Bullock, M., Noble, F., Moutasim, K. A., King, E. V., Vijayanand, P., Mirnezami, A. H., Underwood, T. J., Ottensmeier, C. H., & Thomas, G. J. (2018). Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djx121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.